



### Special Track Session 13

Oncology & Theranostics Committee

#### Debate

Wednesday, September 13, 08:00 – 09:30

#### Session Title

**Staging Lymphoma: Ann Arbour outdated and replaced by Metabolic Tumor Volume?**

#### Moderators

**Irène Buvat**, (Orsay, France)

**Carsten Kobe** (Cologne, Germany)

#### Point of View: Pro

**Anne-Ségolène Cottreau** (Paris, France)

#### Point of View: Contra

**Bastian von Tresckow** (Essen, Germany)

#### Educational Objectives

1. How to use PET for Staging Lymphoma
2. Opportunities when using PET for Staging Lymphoma
3. Limits of Staging Lymphoma using PET

#### Summary

In order to further improve response prediction and risk-adapted individualization of therapy in lymphoma patients, additional risk factors are needed. Such risk factors might include but need not be restricted to the use of metabolic tumor volume, possibly in combination with new biomarkers such as thymus and activation-regulated chemokine or cell free DNA.

#### Key Words

FDG PET, Lymphoma, Staging, Metabolic Tumor Volume, Ann Arbor